Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events

Fränce Hardtstock (), Zeki Kocaata, Thomas Wilke, Axel Dittmar, Marco Ghiani, Vasily Belozeroff, David J. Harrison, Ulf Maywald and Hans Tesch
Additional contact information
Fränce Hardtstock: Ingress-Health HWM GmbH
Zeki Kocaata: Ingress-Health HWM GmbH
Thomas Wilke: IPAM e.V., University of Wismar
Axel Dittmar: IPAM e.V., University of Wismar
Marco Ghiani: IPAM e.V., University of Wismar
Vasily Belozeroff: Amgen Inc.
David J. Harrison: Amgen Inc.
Ulf Maywald: AOK PLUS
Hans Tesch: Centrum for Hematology and Oncology

The European Journal of Health Economics, 2021, vol. 22, issue 2, No 6, 243-254

Abstract: Abstract Background This study analyzes the impact of skeletal-related events (SRE) on healthcare resource utilization (HCRU) and costs incurred by patients with bone metastases (BM) from solid tumors (ST), who are therapy-naïve to bone targeting agents (BTAs). Methods German claims data from 01/01/2010 to 30/06/2018 were used to conduct a retrospective comparative cohort analysis of BTA-naive patients with a BM diagnosis and preceding ST diagnosis. HCRU and treatment-related costs were compared in two matched cohorts of patients with and without a history of SREs, defined as pathological fracture, spinal cord compression, surgery to bone and radiation to bone. The first SRE was defined as the patient-individual index date. Conversely, for the non-SRE patients, index dates were assigned randomly. Results In total, 45.20% of 9,832 patients reported experiencing at least one SRE (n = 4444) while 54.80% experienced none (n = 5388); 2,434 pairs of SRE and non-SRE patients were finally matched (mean age: 70.87/71.07 years; females: 39.07%/38.58%). Between SRE and non-SRE cohorts, significant differences in the average number of hospitalization days per patient-year (35.80/30.80) and associated inpatient-care costs (14,199.27€/10,787.31€) were observed. The total cost ratio was 1.16 (p

Keywords: Bone metastasis; Skeletal-related events; Healthcare resource utilization; Economic burden; Claims data; Bone-targeting agents (search for similar items in EconPapers)
JEL-codes: I11 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-020-01247-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:22:y:2021:i:2:d:10.1007_s10198-020-01247-z

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-020-01247-z

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().